Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagenic Therapeutics, Inc.\newPTIX · Entity 8496 | Director | March 25, 2024 | March 30, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagenic Therapeutics, Inc.\new
Report date March 25, 2024 · Filed March 30, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PTIX Common stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2034-03-25 | Direct | 22,500 |
Reported balance
After 2024-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-25 · Grant · Acquired 22,500 · Balance 22,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2024 Filed Mar 30, 2024 01:29 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantPTIX Common stock Options · Derivative | 22,500 | $1.74 Strike: $1.74 | $39,150.00 |
DisclosureSEC source: 0001493152-24-012070 · ownership.xml · derivative · entry 1 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: PTIX common stock, Par Value $0.0001 · 22,500 shares Expires 2034-03-25 Read SEC document |
| May 26, 2021 Filed Jun 1, 2021 22:54 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantPTIX Common stock NSO Options · Derivative | 180,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001493152-21-013384 · ownership.xml · derivative · entry 1 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: PTIX common stock, Par Value $0.000001 · 180,000 shares Expires 2031-05-26 F1 · derivative.exercise_price: This exercise price was determined by the Board of Directors at a Board Meeting held May 26, 2021. F2 · shares: This number of options was determined by the Board of Directors at a Board Meeting held May 26, 2021. F3 · derivative.exercise_date: The options are fully vested. F2 · derivative.underlying_shares: This number of options was determined by the Board of Directors at a Board Meeting held May 26, 2021. Read SEC document |
| May 03, 2021 Filed May 5, 2021 10:10 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | Exercise / conversionPTIX Common stock Options · Derivative | 120,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001493152-21-010465 · ownership.xml · derivative · entry 8 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: PTIX common stock, Par Value $0.000001 · 120,000 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents a cash exercise of stock options in which the reporting person paid the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| May 03, 2021 Filed May 5, 2021 10:10 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | Exercise / conversionPTIX Common stock Options · Derivative | 45,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001493152-21-010465 · ownership.xml · derivative · entry 7 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: PTIX common stock, Par Value $0.000001 · 45,000 shares Expires 2027-10-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents a cash exercise of stock options in which the reporting person paid the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| May 03, 2021 Filed May 5, 2021 10:10 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | Exercise / conversionPTIX Common stock Options · Derivative | 150,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001493152-21-010465 · ownership.xml · derivative · entry 6 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: PTIX common stock, Par Value $0.000001 · 150,000 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents a cash exercise of stock options in which the reporting person paid the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| May 03, 2021 Filed May 5, 2021 10:10 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | Exercise / conversionPTIX Common stock Options · Derivative | 45,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001493152-21-010465 · ownership.xml · derivative · entry 5 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,000 Underlying: PTIX common stock, Par Value $0.000001 · 45,000 shares Expires 2026-04-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents a cash exercise of stock options in which the reporting person paid the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| May 03, 2021 Filed May 5, 2021 10:10 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | Exercise / conversionProtagenic Therapeutics, Inc. Common Stock | 120,000 | $1.75 | $210,000.00 |
DisclosureSEC source: 0001493152-21-010465 · ownership.xml · nonDerivative · entry 4 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $532,500.00 was paid in cash by the reporting person as consideration for the aggregate option exercise. Read SEC document |
| May 03, 2021 Filed May 5, 2021 10:10 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | Exercise / conversionProtagenic Therapeutics, Inc. Common Stock | 45,000 | $1.75 | $78,750.00 |
DisclosureSEC source: 0001493152-21-010465 · ownership.xml · nonDerivative · entry 3 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $532,500.00 was paid in cash by the reporting person as consideration for the aggregate option exercise. Read SEC document |
| May 03, 2021 Filed May 5, 2021 10:10 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | Exercise / conversionProtagenic Therapeutics, Inc. Common Stock | 150,000 | $1.25 | $187,500.00 |
DisclosureSEC source: 0001493152-21-010465 · ownership.xml · nonDerivative · entry 2 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $532,500.00 was paid in cash by the reporting person as consideration for the aggregate option exercise. Read SEC document |
| May 03, 2021 Filed May 5, 2021 10:10 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | Exercise / conversionProtagenic Therapeutics, Inc. Common Stock | 45,000 | $1.25 | $56,250.00 |
DisclosureSEC source: 0001493152-21-010465 · ownership.xml · nonDerivative · entry 1 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: $532,500.00 was paid in cash by the reporting person as consideration for the aggregate option exercise. Read SEC document |
| February 21, 2020 Filed Feb 27, 2020 01:29 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantPTIX Common stock Options · Derivative | 120,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001493152-20-003041 · ownership.xml · derivative · entry 1 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: PTIX common stock, Par Value $0.0001 · 120,000 shares Expires 2030-02-21 Read SEC document |
| November 05, 2019 Filed Feb 24, 2020 19:16 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | PurchaseConvertible Note · Derivative | Not disclosed | $50,000.00 Strike: $1.25 | $50,000.00 |
DisclosureSEC source: 0001493152-20-002881 · ownership.xml · derivative · entry 1 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common stock, par value $0.0001 per share · 40,000 shares Expires 2023-11-06 F1 · security: The reported transaction is the purchase of a convertible note, convertible at the holder's discretion at any time into common stock at the rate of $1.25 per share. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 18:13 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001437749-17-017233 · rdgdoc.xml · derivative · entry 1 Barrage Khalil · CIK 0001666011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Protagenic Therapeutics, Inc. Common Stock · 45,000 shares Expires 2027-10-16 F1 · derivative.exercise_date: Vesting in equal installments over 18 months Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.